Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 6, 2007, Pages 846-851

  Ibañez, Patricio ^a   Solis, Nancy ^a   Pizarro, Margarita ^a   Aguayo, Gloria ^a   Duarte, Ignacio ^a   Miquel, Juan Francisco ^a   Accatino, Luigi ^a   Arrese, Marco ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Hepatic fibrosis; Losartan; Renin angiotensin system; Steatohepatitis; Transforming growth factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA ACTIN; ASPARTATE AMINOTRANSFERASE; CHOLINE; HYDROXYPROLINE; LOSARTAN; MESSENGER RNA; PROCOLLAGEN; TRANSFORMING GROWTH FACTOR BETA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMISTRY; CELL ACTIVATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET; FIBROGENESIS; HISTOLOGY; IMMUNOFLUORESCENCE; LIVER; LIVER FIBROSIS; LIVER INJURY; MALE; MORPHOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; STELLATE CELL;

EID: 34250360749     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04700.x     Document Type: Article

References (30)

1. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003 37 : 1202 19.
2. Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin. Liver Dis. 2004 8 : 501 19.
3. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002 346 : 1221 31.
4. Yoshioka Y, Hashimoto E, Yatsuji S et al. Nonalcoholic steatohepatitis. cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J. Gastroenterol. 2004 39 : 1215 18.
5. Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease/non- alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract. Res. Clin. Gastroenterol. 2004 18 : 1089 104.
6. Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002 123 : 134 40.
7. Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004 27 : 2057 66.
8. Sanyal AJ. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2005 2 : 46 53.
9. Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin. Biochem. 2005 38 : 203 17.
10. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006 43 : S99 112.
11. Day CP, James OF. Steatohepatitis: a tale of two 'hits'? Gastroenterology 1998 114 : 842 5.
12. Day C, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J. Gastroenterol. Hepatol. 2002 17 (Suppl. 3 S377 84.
13. Day CP. Pathogenesis of steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 2002 16 : 663 78.
14. Ramesh S, Sanyal AJ. Evaluation and management of non-alcoholic steatohepatitis. J. Hepatol. 2005 42 (Suppl. S2 12.
15. Tilg H, Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2005 2 : 148 55.
16. Albanis E, Friedman SL. Antifibrotic agents for liver disease. Am. J. Transplant. 2006 6 : 12 19.
17. Yoshiji H, Kuriyama S, Yoshii J et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001 34 : 745 50.
18. Bataller R, Sancho-Bru P, Gines P, Brenner DA. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid. Redox Signal. 2005 7 : 1346 55.
19. Sica DA. Pharmacotherapy review: angiotensin receptor antagonists. J. Clin. Hypertens. (Greenwich) 2005 7 : 681 4.
20. Sookoian S, Fernandez MA, Castano G. Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study. World J. Gastroenterol. 2005 11 : 7560 3.
21. Yokohama S, Yoneda M, Haneda M et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004 40 : 1222 5.
22. Hironaka K, Sakaida I, Uchida K, Okita K. Correlation between stellate cell activation and serum fibrosis markers in choline-deficient 1-amino acid-defined diet-induced rat liver fibrosis. Dig. Dis. Sci. 2000 45 : 1935 43.
23. Croquet V, Moal F, Veal N et al. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J. Hepatol. 2002 37 : 773 80.
24. Washington K, Wright K, Shyr Y, Hunter EB, Olson S, Raiford DS. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum. Pathol. 2000 31 : 822 8.
25. Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J. Hepatol. 2004 41 : 592 8.
26. Perier C, Ronziere MC, Rattner A, Frey J. Employment of gas-liquid chromatography for the analysis of collagen amino acids in biopsy tissue. J. Chromatogr. 1980 182 : 155 62.
27. Honda H, Ikejima K, Hirose M et al. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 2002 36 : 12 21.
28. Martinez-Prieto C, Ortiz MC, Fortepiani LA, Ruiz-Macia J, Atucha NM, Garcia-Estan J. Haemodynamic and renal evolution of the bile duct-ligated rat. Clin. Sci. (Lond.) 2000 98 : 611 17.
29. Keogh KA, Standing J, Kane GC, Terzic A, Limper AH. Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice. Eur. Respir. J. 2005 25 : 708 14.
30. Yao HW, Zhu JP, Zhao MH, Lu Y. Losartan attenuates bleomycin-induced pulmonary fibrosis in rats. Respiration 2006 73 : 236 42.